Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

T 20K

Next Previous
Search
Drug Profile

T 20K

Alternative Names: T-20K

Latest Information Update: 28 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cyxone
  • Developer Cyxone; University of Vienna
  • Class Anti-inflammatories; Neuroprotectants; Peptides
  • Mechanism of Action Interleukin 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple sclerosis

Highest Development Phases

  • No development reported Inflammatory bowel diseases; Multiple sclerosis

Most Recent Events

  • 28 Nov 2024 No recent reports of development identified for phase-I development in Multiple-sclerosis(In volunteers) in Netherlands (Parenteral, Infusion)
  • 25 Nov 2022 Phase-I development in Multiple sclerosis (In volunteers) is ongoing in Netherlands (Parenteral, infusion) (Cyxone pipeline, November 2022)
  • 25 Nov 2022 T 20K is available for licensing as of 25 Nov 2022. https://cyxone.com/en/projects/multiple-sclerosis/

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top